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Abstract
Background: Low density arrays (LDAs) have recently been introduced as a novel approach to
gene expression profiling. Based on real time quantitative RT-PCR (QRT-PCR), these arrays enable
a more focused and sensitive approach to the study of gene expression than gene chips, while
offering higher throughput than more established approaches to QRT-PCR. We have now
evaluated LDAs as a means of determining the expression of multiple genes simultaneously in
human tissues and cells.
Results: Comparisons between LDAs reveal low variability, with correlation coefficients close to
1. By performing 2-fold and 10-fold serial dilutions of cDNA samples in the LDAs we determined
a clear linear relationship between the gene expression data points over 5 orders of magnitude.
We also showed that it is possible to use LDAs to accurately and quantitatively detect 2-fold
changes in target copy number as well as measuring genes that are expressed with low and high
copy numbers in the range of 1 × 102 – 1 × 106 copies. Furthermore, the data generated by the
LDA from a cell based pharmacological study were comparable to data generated by conventional
QRT-PCR.
Conclusion:  LDAs represent a valuable new approach for sensitive and quantitative gene
expression profiling.
Background
Gene expression analysis provides a view of transcrip-
tional activity and regulation, which is useful as an indica-
tor of likely protein expression and potential function.
The current approaches to measuring gene expression vary
from parallel semi-quantitative measurements of large
numbers of mRNA transcripts in a single sample, using
gene chip technologies, to focussed sensitive approaches,
such as QRT-PCR, that enable quantitative evaluation of
the expression of single genes in multiple samples [1,2].
While gene chip technology offers the means to carry out
hypothesis-free investigation of the expression of a large
number of genes, a major disadvantage of this technology
is its lack of sensitivity. In contrast, QRT-PCR is currently
capable of measuring single genes in a uniquely robust
and sensitive fashion being capable of detecting specific
mRNAs at levels as low as 1 copy per 5,000 cells (1 copy
in 10 ng of total RNA).
For some time, there have been attempts to identify tech-
nologies that can facilitate more quantitative and sensitive
expression profiling of a number of genes in single sam-
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ples simultaneously. In this present study, the potential of
one such technology (Low Density Array. LDA; Applied
Biosystems; CA, USA) has been assessed. LDA technology
is based on the QRT-PCR platform, therefore, while
retaining the sensitivity of QRT-PCR, LDAs are claimed to
allow the simultaneous quantification of large numbers
of target genes in single samples [3]. Consequently, LDA
technology could be used to compare levels of expression
of panels of specific genes in treated and untreated cells in
vitro, and also to look at the relative expression levels of
panels of genes in diseased versus non-diseased tissues.
In the current study, the potential of LDAs for the evalua-
tion of gene expression profiles in human cells and tissues
has been assessed. Key features of the assessment included
ease of use, sensitivity and reproducibility. In addition, to
evaluate the ability of LDAs to allow the accurate measure-
ment of changes in the expression of multiple genes, the
technique was applied to thrombin-stimulated human
endothelial cells, and the results compared with those
generated using conventional QRT-PCR.
Results
Variability of gene expression data derived from LDAs
A single sample of cDNA from human liver was run down
all eight channels of three identical LDAs from the same
production batch. The data derived across these LDAs
were virtually identical, with correlation coefficients
approximating unity (LDA 1 vs 2, 0.96. LDA 1 vs 3, 0.96.
LDA 2 vs 3, 0.97). These data therefore demonstrate neg-
ligible variation between arrays from the same batch. Rep-
resentative data are displayed graphically in Figure 1. Ct
values (the fractional cycle number at which a PCR prod-
uct is first detected) for LDA 1 have been plotted against
Ct values for LDA 2. The results are more reproducible at
the lower Ct values (higher copy numbers) when com-
pared to the higher Ct values, where detection limits of the
system are being approached.
The data generated for LDAs 1–3 were used to assess the
quadruplicated values for each gene on each LDA, and
also to look at the variation of the 12 values across the
three LDAs. The data showed low coefficient of variation
(CV%) between wells within a single LDA, and between
LDAs. As expected, the CV% increased with lower gene
expression levels i.e. higher Cts. Combined data for all tar-
gets across the three identical arrays are shown in Table 1.
Fidelity and dynamic range of LDAs
For the liver cDNA, 2-fold dilution plots are shown (Fig-
ure 2) for two genes, 18S-ribosomal RNA (18S), which
showed high expression in the liver, and BCL2, which
exhibited much lower expression. These results demon-
strate that these two primer probe sets generate linear
results over the expression range studied, with R2 values
close to 1 being obtained.
These data demonstrate that using the LDAs it is possible
to accurately detect 2-fold changes in target copy number.
They also demonstrate that these small changes can be
detected at both low Cts (high expression) and high Cts
(low expression), within the approximate range of 1 × 102
– 1 × 106 copies.
For the 10-fold dilution series of cDNA (derived from ton-
sil), the R2values were also determined, Figure 3, shows
examples of the plots generated for two genes, HLA-DRA,
which was highly expressed in the tonsil, and CD26E,
which had lower expression. For CD26E, with a higher
starting Ct value, it was not possible to plot all the points
in the dilution series, as the sample was diluted beyond
the level of detection. However, for both genes, we deter-
mined a clear linear relationship between the gene expres-
LDAs Ct (copy threshold) data plotted LDA 1 vs 2; 1 vs 3  and 2 vs 3 Figure 1
LDAs Ct (copy threshold) data plotted LDA 1 vs 2; 1 
vs 3 and 2 vs 3. The x and y-axis represent Ct values 
obtained from LDA 1 and 2, LDA 1 and 3 and LDA 2 and 3 
respectively. A line of best fit has been plotted.
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Table 1: Analysis of the gene expression values, for LDA 1–3
Gene Ct Mean CV% Gene Ct Mean CV%
18S-4342379-18S 14.62 0.44 TNF-a-Hs00174128_m1 31.66 1.42
C3-Hs00163811_m1 19.37 1.96 ITAC-Hs00171138_m1 32.05 1.63
FN precursor-Hs00365052_m1 21.87 1.75 CD62E (SELP)-Hs00174583_m1 32.09 1
GAPDH-4342376-GAPDH 22.25 1.59 ACE-Hs00174179_m1 32.1 4.55
Stat3-Hs00234174_m1 23.76 0.88 CD25-Hs00166229_m1 32.57 1.27
HLA-DRA-Hs00219575_m1 25.2 0.86 CCR5-Hs00152917_m1 33.1 2.14
CD54 (ICAM)-Hs00164932_m1 25.47 1.05 IL-6-Hs00174131_m1 33.56 3.15
HO-1-Hs00157965_m1 25.8 0.84 IL-18-Hs00155517_m1 33.78 1.96
GUSB-Hs99999908_m1 25.98 0.6 CCR4-NM_005508 33.78 5.99
CD68-Hs00154355_m1 26.08 0.88 COX-2-Hs00153133_m1 33.79 1.7
VEGF A-Hs00173626_m1 26.24 1.47 FasL-Hs00181225_m1 33.83 2.83
TGF-b-Hs00171257_m1 26.32 1.59 MEGALIN-Hs00189742_m1 33.87 3.01
MCP-1-Hs00234140_m1 26.68 1.02 CD154(TNFSF5)-Hs00163934_m1 33.96 2.01
NFKB2-Hs00174517_m1 27.2 1.1 CD34-Hs00156373_m1 34.31 2.68
BAX-Hs00180269_m1 27.21 1.05 MADH-3-Hs00232219_m1 34.66 6.11
ECE-1-Hs00154837_m1 27.31 1.77 AT1R(AGTR1)-Hs00241341_m1 34.91 3.29
Mip-1a-Hs00234142_m1 27.55 0.95 CD28-Hs00174796_m1 34.95 3.63
CYP1A2-Hs00167927_m1 27.56 1.03 Collagen IV(COL4A5)-Hs00166712_m1 35 2.2
IkB2-Hs00395088_m1 28 0.77 T-bet (TBX21)-Hs00203436_m1 35.73 4.16
IL-1b-Hs00174097_m1 28.23 2.32 CYP7A1-Hs00167982_m1 35.83 7.25
CD45-Hs00365634_g1 28.25 1.12 GZMB-Hs00188051_m1 35.86 3.05
CD38-Hs00233552_m1 28.33 0.7 TNF-b-Hs00236874_m1 36.34 10.21
GNLY-Hs00246266_m1 28.38 1.65 IFN-g-Hs00174143_m1 36.69 7.65
CSF-1-Hs00174164_m1 28.49 1.18 CD19-Hs00174333_m1 37.32 6.42
CD40-Hs00374176_m1 28.71 0.93 CD152-Hs00175480_m1 37.33 7.63
HLADR-NM_002124 28.77 1.01 IL-15-Hs00174106_m1 37.51 2.79
Rantes-Hs00174575_m1 28.82 1.11 IL-12p35-Hs00168405_m1 37.55 4.59
Mip-3c-Hs00171149_m1 28.88 1.64 CCR7-Hs00171054_m1 37.8 4.16
Fas-Hs00163653_m1 28.99 2.07 ICOS-Hs00359999_m1 37.96 5.78
CD71-Hs99999911_m1 29.02 1.04 CXCR3-Hs00171041_m1 38.23 5.79
IL-7-Hs00174202_m1 29.51 1.84 IL-1a-Hs00174092_m1 38.9 3.39
SKI-Hs00161707_m1 29.63 2.05 IL-3-Hs00174117_m1 39 6
MADH-7-Hs00178696_m1 30.19 1.2 IL-5-Hs00174200_m1 39.08 5.75
Beta Actin-Hs00174609_m1 30.27 1.48 IL-17-Hs00174383_m1 39.22 4.63
PRF1-Hs00169473_m1 30.43 1.24 iNos(Nos2A)-Hs00167248_m1 39.24 4.54
BCL-XL-Hs00169141_m1 30.49 1.75 IL-2-Hs00174114_m1 39.26 4.46
CD8-Hs00233520_m1 30.59 1.3 IL-12p40-Hs00233688_m1 39.45 3.28
CD4-Hs00181217_m1 30.6 2.25 IL-9-Hs00174125_m1 39.73 2.32
IL-8-Hs00174103_m1 30.69 3.06 RENIN(REN)-Hs00166915_m1 39.78 1.94
BCL2-Hs00153350_m1 30.84 1.17 AT2R(AGTR2)-Hs00169126_m1 40 0
CD3-Hs00167894_m1 31.06 1.8 CCR2-Hs00174150_m1 40 0
IL-10-Hs00174086_m1 31.16 1.29 CSF-2-Hs00171266_m1 40 0
CD62E (SELE)-Hs00174057_m1 31.33 1.29 CSF-3-Hs00357085_g1 40 0
IP10-Hs00171042_m1 31.42 1.22 GITR(TNFRSF18)-Hs00188346_m1 40 0
CD86-Hs00199349_m1 31.42 1.59 IL-13-Hs00174379_m1 40 0
Endothelin(EDN1)-Hs00174961_m1 31.48 1.26 IL-4-Hs00174122_m1 40 0
CD80-Hs00175478_m1 31.49 1.81 MYH6-Hs00411908_m1 40 0
This table shows the mean data (from liver cDNA) generated from the 94 primer probe sets across the three arrays of the same format. There 
were quadruplicate determinations for each gene on each card so the table represents 12 measurements for each gene. Mean Ct (copy threshold) 
and coefficient of variation (CV%) have been calculated.
sion data points and for HLA-DRA linearity was obtained
over 5 log base 10 dilutions.
Comparing efficiencies of the 96 primer probe sets
For the liver cDNA 2-fold dilution series, R2 values and
slopes were determined by linear regression analysis. Data
for all genes are shown in Table 2. The Ct values of the
undiluted cDNA for the targets range from 14.7 to 40 with
good linearity for most of the targets over the 2-fold dilu-
tion series, most with R2 values close to 1. However over
the range of Ct values the slopes vary, 18S (mean Ct
14.71) has a slope of -2.72 whereas BCL2 (mean CtBMC Genomics 2006, 7:34 http://www.biomedcentral.com/1471-2164/7/34
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31.22) has a slope of -4.08. This data indicates different
amplification efficiencies of the primer probe sets.
Comparison of gene expression profiles derived using LDAs 
with those derived using conventional QRT-PCR
The levels of IL-8, MCP-1 and RANTES were quantified
using conventional QRT-PCR and LDA-based QRT-PCR in
control and thrombin-treated human aortic endothelial
cells (HAECs) at 2 and 12 hour time points (see Figure 4).
Both approaches produced qualitatively and quantita-
tively similar data in that the expression of all three genes
was up-regulated by thrombin to similar degrees. Thus,
conventional QRT-PCR showed that IL-8 was up-regu-
lated by 10-fold at 2 hours, and by 13-fold at 12 hours,
while the LDA-derived data demonstrated a 9-fold
increase in IL-8 at 2 hours, and 10-fold at 12 hours. MCP-
1 expression data showed similar trends whether meas-
ured by either system, with 2 and 5-fold increases in the
levels of transcript at 2 and 12 hours respectively, follow-
ing incubation with thrombin. The level of basal RANTES
expression was low, however, it was still possible using
conventional and LDA-based QRT-PCR to demonstrate
up-regulation in expression 12 hours post-thrombin.
As the LDAs contained 96 primer probe sets in quadrupli-
cate, it was possible to assess the effects of thrombin treat-
ment on many more genes in a single sample than would
be possible with conventional QRT-PCR. Of the 96 genes
investigated, 16 at two hours and 13 at 12 hours were
changed by more than 50% from the control. For all tar-
gets for which gene expression was changed by more than
50% the majority were up-regulated in response to
thrombin, with only two genes being down-regulated
(Figure 5).
Where target expression was compared between treatment
and control groups, the expression levels of housekeeping
genes (conventional QRT-PCR; β-actin, transferrin recep-
tor and GAPDH. LDA QRT-PCR; 18S, β-actin and
GAPDH), were comparable in the treated and control
samples (data not shown).
Discussion
Gene expression provides a view of transcriptional activity
and regulation, and is often used as a surrogate marker for
protein levels. Analysis of gene expression is used in a vari-
ety of studies, which range from identifying target genes
that are altered in diseased tissues, to the screening of
chemical libraries in phenotypic assays. The current
approaches to measuring gene expression vary from tech-
nologies that involve parallel quantification of large num-
bers of mRNA transcripts in single samples (for example,
using gene chip technologies) to very focussed approaches
(such as QRT-PCR) that look at the expression of single
genes in multiple samples. For some time, a technology
has been sought that combines the ability to measure the
expression of many genes in a single sample as with the
chip array approach, while retaining the sensitivity and
quantitative capacity offered by QRT-PCR. We have now
evaluated the potential of LDA as such a technology.
Measurement by LDA of mRNA's for two genes (CD26E and  HLA-DRA) derived from a 10-fold dilution series of tonsil  cDNA Figure 3
Measurement by LDA of mRNA's for two genes 
(CD26E and HLA-DRA) derived from a 10-fold dilu-
tion series of tonsil cDNA. Each data point represents the 
mean Ct (copy threshold) value derived from quadruplicate 
measurement of each sample dilution. A line of best fit and R2 
value were derived using PRISM software.
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Measurement by LDA of mRNA's for two genes (BCL2 and  18S) derived from a 2-fold dilution series of liver cDNA Figure 2
Measurement by LDA of mRNA's for two genes 
(BCL2 and 18S) derived from a 2-fold dilution series 
of liver cDNA. Each data point represents the mean Ct 
(copy threshold) value derived from quadruplicate measure-
ment of each sample dilution. A line of best fit and R2 value 
were derived using PRISM software.
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The aim of the study was therefore to assess the LDA tech-
nology, and to determine whether it is capable of detect-
ing and measuring changes in a large number of genes
simultaneously in a sensitive, robust and accurate man-
ner. Initially, we set out to investigate the variability of the
technique. cDNA from one common liver sample was
loaded in all channels across three arrays. Each gene was
investigated in quadruplicate on each of the three arrays
(all from the same batch). This facilitated investigating the
variability across the quadruplicate values for each array
and between triplicate arrays. The resulting data indicate
that the variability between LDAs within a batch is low,
with correlation coefficients for between array compari-
sons all being greater than 0.96. Additionally, analysis of
the quadruplicate value for each gene on individual arrays
revealed a low % CV, indicating a high level of reproduci-
bility of data within each array. However, the current
study has not addressed variability between cards from
different batches and so the possibility exists of larger var-
iation occurring between LDAs from different batches.
Having determined that the variability within and
between the arrays was low, we next wanted to determine
how capable the LDAs are of accurately quantifying small
Table 2: Linear regression analysis of the 2-fold dilution data
Gene Mean Ct Slope R2 Gene Mean Ct Slope R2
18S-4342379-18S 14.71 -2.72 0.96 CD62E (SELE)-Hs00174057_m1 31.55 -6.53 0.93
C3-Hs00163811_m1 19.83 -3.92 0.97 IL-8-Hs00174103_m1 31.55 -5.83 0.87
FN precursor-Hs00365052_m1 22.29 -3.85 0.97 IP10-Hs00171042_m1 31.75 -4.24 0.94
GAPDH-4342376-GAPDH 22.7 -3.55 0.98 Endothelin(EDN1)-Hs00174961_m1 31.77 -5.45 0.82
Stat3-Hs00234174_m1 24.03 -3.7 0.98 CD86-Hs00199349_m1 31.78 -5.3 0.93
HLA-DRA-Hs00219575_m1 25.37 -3.87 0.99 CD80-Hs00175478_m1 31.81 -5.14 0.86
CD54 (ICAM)-Hs00164932_m1 25.75 -3.74 0.99 TNF-a-Hs00174128_m1 31.84 -4.15 0.92
HO-1-Hs00157965_m1 26 -3.71 0.99 CD62E (SELP)-Hs00174583_m1 32.41 -5.07 0.96
GUSB-Hs99999908_m1 26.09 -3.67 0.97 CD25-Hs00166229_m1 32.44 -5.2 0.94
CD68-Hs00154355_m1 26.36 -4.02 0.99 ITAC-Hs00171138_m1 32.61 -5.3 0.94
VEGF A-Hs00173626_m1 26.63 -3.88 0.98 ACE-Hs00174179_m1 33.1 -4.33 0.82
TGF-b-Hs00171257_m1 26.78 -3.82 0.95 CCR5-Hs00152917_m1 33.77 -4.76 0.94
MCP-1-Hs00234140_m1 26.99 -3.85 0.98 IL-18-Hs00155517_m1 33.98 -4.25 0.88
BAX-Hs00180269_m1 27.51 -4.7 0.98 MEGALIN-Hs00189742_m1 34.1 -2.98 0.55
NFKB2-Hs00174517_m1 27.53 -3.87 0.98 COX-2-Hs00153133_m1 34.3 -3.35 0.86
CYP1A2-Hs00167927_m1 27.81 -3.71 0.99 CD154(TNFSF5)-Hs00163934_m1 34.57 -3.16 0.73
ECE-1-Hs00154837_m1 27.81 -3.81 0.97 IL-6-Hs00174131_m1 34.59 -4.09 0.93
Mip-1a-Hs00234142_m1 27.88 -3.74 0.99 FasL-Hs00181225_m1 34.74 -4 0.9
IkB2-Hs00395088_m1 28.24 -5.23 0.91 CCR4-NM_005508 34.99 -3.49 0.96
IL-1b-Hs00174097_m1 28.33 -5.27 0.9 CD34-Hs00156373_m1 35.3 -3.01 0.88
CD38-Hs00233552_m1 28.5 -3.41 0.98 CD28-Hs00174796_m1 35.53 -2.41 0.8
CD45-Hs00365634_g1 28.63 -4.16 0.98 AT1R(AGTR1)-Hs00241341_m1 35.53 -3.28 0.83
GNLY-Hs00246266_m1 28.74 -3.5 0.89 Collagen IV(COL4A5)-Hs00166712_m1 35.71 -3.2 0.82
CSF-1-Hs00174164_m1 28.86 -4.09 0.98 T-bet (TBX21)-Hs00203436_m1 35.75 -3.14 0.87
CD40-Hs00374176_m1 29.01 -3.49 0.98 CD19-Hs00174333_m1 36.35 -1.78 0.71
HLADR-NM_002124 29.11 -4.32 0.97 IL-12p35-Hs00168405_m1 36.57 -2.48 0.88
CD71-Hs99999911_m1 29.19 -3.7 0.98 IFN-g-Hs00174143_m1 36.84 -2.12 0.88
Rantes-Hs00174575_m1 29.19 -4.52 0.97 GZMB-Hs00188051_m1 36.99 -1.83 0.77
Mip-3c-Hs00171149_m1 29.43 -4.57 0.98 MADH-3-Hs00232219_m1 37.1 -2.21 0.79
Fas-Hs00163653_m1 29.5 -5.89 0.87 CYP7A1-Hs00167982_m1 37.17 -2.48 0.63
IL-7-Hs00174202_m1 29.74 -6.84 0.9 CD152-Hs00175480_m1 37.28 -1.46 0.64
SKI-Hs00161707_m1 30.31 -3.89 0.96 CXCR3-Hs00171041_m1 37.62 -1.24 0.49
MADH-7-Hs00178696_m1 30.48 -5.13 0.93 IL-15-Hs00174106_m1 37.92 -1.38 0.77
Beta Actin-Hs00174609_m1 30.57 -4.52 0.92 CCR7-Hs00171054_m1 38.15 -1.34 0.85
CD8-Hs00233520_m1 30.68 -4.61 0.99 iNos(Nos2A)-Hs00167248_m1 38.86 -0.54 0.43
PRF1-Hs00169473_m1 30.73 -4.22 0.9 IL-17-Hs00174383_m1 38.92 -0.51 0.43
BCL-XL-Hs00169141_m1 30.78 -3.37 0.99 TNF-b-Hs00236874_m1 38.97 -0.8 0.12
BCL2-Hs00153350_m1 31.22 -4.08 0.98 ICOS-Hs00359999_m1 38.98 -0.9 0.81
IL-10-Hs00174086_m1 31.33 -5.37 0.97 IL-5-Hs00174200_m1 38.98 -0.99 0.24
CD4-Hs00181217_m1 31.35 -4.93 0.97 IL-1a-Hs00174092_m1 39.39 -0.51 0.78
CD3-Hs00167894_m1 31.42 -5.68 0.93
This table shows data (from liver cDNA) generated from the 96 primer probe sets. There were quadruplicate determinations for each sample 
dilution. Mean Ct (copy threshold) of the undiluted liver cDNA is given for each gene. The slope and R2 values have been calculated. Genes with Ct 
values of 40 have not been included in the table.BMC Genomics 2006, 7:34 http://www.biomedcentral.com/1471-2164/7/34
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IL-8, MCP-1 and RANTES expression in human aortic endothelial cells measured using Conventional- and LDA-QRT-PCR Figure 4
IL-8, MCP-1 and RANTES expression in human aortic endothelial cells measured using Conventional- and 
LDA-QRT-PCR. White bar; control-2 hrs. Yellow bar; control-12 hrs. Blue bar; thrombin-2 hrs. Red bar; thrombin-12 hrs. 
Each bar represents the geometric mean copy number (n = 3) +95 % CI.
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changes in gene expression. Linear regression analysis of
the 2-fold serial dilution of liver cDNA across 6 LDAs
showed for most genes, R2 values close to 1, indicating a
clear linear relationship of the gene expression data points
over the range of the dilution series. The data demonstrate
that LDAs are able to accurately and quantitatively detect
2-fold changes in target copy number as was demon-
strated using a serial dilution of cDNA. It is hoped that the
LDA cards will demonstrate the same fidelity in other
experimental scenarios including those where 2 different
RNA preparations are used from treated cells and
untreated control cells. The data in Figures 4 and 5 sup-
port this, whereby modest changes were observed. In
addition to assessing the accuracy and ability of the LDAs
to detect small changes in gene expression, the linear
regression analysis enabled the assessment of the slopes
for each gene, with the slope indicating the efficiency of
the primer probe set. The efficiencies of the primer probe
sets used in this study did vary and so the delta delta Ct
analysis system utilised by the ABI software for analysing
the LDA data may not always be appropriate (see data
analysis section) as it works on the principle that the effi-
ciencies of the different primer probe sets are comparable.
Next, we sought to assess whether LDAs are equally capa-
ble of detecting genes that are present at low and high
copy numbers. Comparison of the dynamic range of LDAs
was carried out using a 10-fold serial dilution of cDNA
prepared from tonsil. The same channels (same genes) of
6 separate LDA cards were loaded with six concentrations
of tonsil cDNA. For targets with a copy threshold of less
than 40 (within the limits of detection) across the concen-
tration range, a dynamic range of the system over 5 orders
of magnitude was demonstrated, indicating that it is pos-
sible to accurately and quantitatively detect genes at high
and low copy numbers. This data is in agreement with a
recent study using LDA cards, which found the technology
had a wide dynamic range, up to seven orders of magni-
tude [3].
Having built confidence regarding the sensitivity, repro-
ducibility and dynamic range of LDAs, the next step was
to apply them to an experimental situation and compare
the data with those generated using conventional QRT-
PCR. Thus, both techniques were used to evaluate
thrombin-induced changes in gene expression in human
aortic endothelial cells. The study focused on three genes,
IL-8, MCP-1 and RANTES, which are implicated in athero-
sclerosis [4-6]. The resulting data indicate that LDAs pro-
duced qualitatively and quantitatively similar data to
conventional QRT-PCR. Both techniques indicated that
thrombin caused up-regulation in the three key genes of
interest (IL-8, MCP-1, RANTES). This suggests that LDAs
are suitable for examining changes in gene expression in
response to pharmacological stimuli.
A key advantage of LDAs over conventional QRT-PCR is
their ability to assess changes in multiple genes in a single
sample. Therefore, in the current study in thrombin-
treated cells, in addition to demonstrating that IL-8, MCP-
1 and RANTES are up-regulated, the LDAs provided data
on a further 93 genes. Of these genes, the expression levels
of 16 at 2 hours and 13 at 12 hours were changed by more
than 50% from the control. From the genes whose expres-
sion was changed by more than 50%, the majority were
up-regulated in response to thrombin, with only two
genes being down-regulated. These additional data dem-
onstrate the power of the LDA technology to investigate
changes in expression of a large number of genes simulta-
neously in a single study in a sensitive and quantitative
manner. In the present study, in addition to demonstrat-
ing the expected thrombin-induced increase in IL-8 and
MCP-1 mRNA, the LDAs detected for the first time that
Quantification of changes in gene expression in thrombin  treated human aortic endothelial cells determined using the  LDA based QRT-PCR Figure 5
Quantification of changes in gene expression in 
thrombin treated human aortic endothelial cells 
determined using the LDA based QRT-PCR. Each bar 
represents the fold change from control (n = 3; based on 
geometric mean data) at 2 hours (A) and 12 hours (B) post-
thrombin. Targets that were altered by less than 50 % from 
the control were excluded from this figure.
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thrombin regulates several other genes (CSF-2, CSF-3,
MADH-3 and MADH-7) in human endothelial cells.
Other considerations that are also important in assessing
this new technology are its ease of use and cost implica-
tions. Loading and setting up the LDA cards was straight-
forward, with no requirement for robotic liquid handling.
The cost of conducting studies on the LDAs is less than
that of conventional QRT-PCR. This primarily reflects the
savings made in time and money through not having to
design and purchase specific primer probe sets. Addition-
ally, LDAs require a very low reaction volume, which
means that there are large savings in master mix, and a
reduction in the use of RNA per study. In the current study
involving 20 LDAs, we calculated the savings relative to
carrying out the study using conventional QRT-PCR to be
in the order of 60% on time and 70% on consumable
cost.
Conclusion
In conclusion, this study has shown that LDA technology
provides a sensitive and reproducible approach to study
gene expression. In addition, this new technique has been
shown to produce comparable results to those produced
by conventional QRT-PCR. However, LDAs have the
advantage of allowing multiple genes to be studied from
a single sample, and also offer savings in terms of costs
and materials. Therefore, LDAs represent a valuable new
approach to sensitive and quantitative gene expression
profiling.
Methods
The human tissues used in this study were obtained
through partnership with medical intermediaries, hospi-
tals and tissue banks, in all cases with the full informed
consent of the donor or their next of kin, and with
approval from the appropriate ethics committees. RNA
was extracted from tissue using TriZol (Invitrogen Life
technologies, Paisley, UK), a commercially available mix-
ture of organic solvents according to the manufacturer's
protocol.
For primary cell studies, human aortic endothelial cells
(Cambrex, Nottingham, UK) (passage 4) maintained in
EGM-2 (Cambrex) were plated out in collagen-coated 96-
well plates, and allowed to reach approximately 80-90 %
confluence (6 × 104 cells/well). Eighteen hours before
commencement of the thrombin treatment, the culture
medium was removed and replaced with basal medium,
EBM-2 (Cambrex,) containing 2 % FBS. At time point
zero, the cells were incubated with thrombin (6 Units/ml,
in EBM-2), or media. The cells were incubated for 2 and
12 hours at 37°C; at 5% humidity; in 95% O2; 5% CO2.
After the incubation period, the medium was removed
from the cells, and the total RNA was extracted immedi-
ately using RNeasy extraction kits (Qiagen, West Sussex,
UK) according to the manufacturer's protocol. To ensure
the quality of the data, RNA was extracted from an equal
number of cells. Each treatment was performed in tripli-
cate and pooled. For the LDA cards the RNA samples
loaded were derived from 3 donors. The expression levels
of the housekeeping genes, β-actin, transferrin receptor
and GAPDH, were measured in each sample using con-
ventional QRT-PCR (data not shown). The levels of
expression of the house keeping genes across the samples
were not significantly different (student's paired t test on
the log10  transformed data). Furthermore, equivalent
expression as confirmed by the equivalence test [7] for
dependent samples was identified for β-actin, transferrin
receptor and GAPDH. Hence, normalisation of the data
against a single housekeeping gene was not carried out.
Quantification of specific mRNAs by conventional QRT-
PCR was carried out using previously described method-
ology [8]. Total RNA samples were treated with RNase-free
DNase I (amplification grade; Invitrogen Life Technolo-
gies) according to the manufacturers' instructions. PCR
was then carried out in absence of reverse transcriptase to
ensure the removal of all genomic DNA. For each RNA
sample, total RNA was then used as template for first
strand cDNA synthesis. The RNA in a volume of 4 µl and
in the presence of reverse primers for IL8, MCP1, RANTES
and GAPDH, 1 × PCR buffer II (Applied Biosystems), and
5 mM MgCl2 was heated to 72°C for 5 min and cooled
slowly to 55°C. After addition of all other reagents, the 6
µl reaction was incubated at 37°C for 30 min followed by
an enzyme inactivation step of 90°C for 5 min. The final
reaction conditions for reverse transcription were as fol-
lows: 1 × PCR buffer II; 5 mM MgCl2; 1 M dATP, dGTP,
and dCTP, 2 mM dTTP; 12.5 U MuLV reverse transcriptase
(Invitrogen Life Technologies). The resulting cDNA was
subjected to PCR amplification in the ABI 7700 or 7900
Sequence Detection System to identify either IL8, MCP1
or RANTES PCR product in conjunction with GAPDH
transcripts in a single reaction, appropriate positive and
negative PCR controls were also included. Final reaction
conditions were 4% glycerol; 0.66 × TaqMan buffer A
(Applied Biosystems); 6 mM MgCl2; 358 µM dATP, dUTP,
dGTP, and dCTP; 2.5 U AmpliTaq Gold; and 0.16 U of
AmpErase UNG (uracil N-glycosylase). An initial enzyme
activation step of 94°C for 12 min was followed by 40
PCR cycles each of 95°C for 15 s, 60°C for 30 s. Forward
and reverse primers and flurogenic probes were designed
to the targets of interest using Primer Express software
(Applied Biosystems). All the probes were quenched with
carboxytetramethyl rhodamine, and labelled with the
fluor, 6-carboxyfluorescein. The primer probe sequences
used in conventional QRT-PCR were designed using
Primer Express. They were homology searched against all
known sequences. The efficiency of the primer probe setsBMC Genomics 2006, 7:34 http://www.biomedcentral.com/1471-2164/7/34
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conformed to the global standard curve described by
Bowen et al [8]. Additionally the PCR products for all
primer probe sets were run down a 4% agarose gel and for
all of the sets investigated a single band of the expected
molecular weight was observed.
IL-8, Accession number NM_000584.
Forward 5' CTGGCCGTGGCTCTCTTG 3'
Reverse 5' CCTTGGCAAAACTGCACCTT 3'
Probe 5' CAGCCTTCCTGATTTCTGCAGCTCTGTGT 3'
MCP-1 Accession number NM_002982.
Forward 5' CGCCTCCAGCATGAAAGTCT 3'
Reverse 5' GGAATGAAGGTGGCTGCTATG 3'
Probe 5' TGCCGCCCTTCTGTGCCTGC 3'
RANTES Accession number NM_002985.
Forward 5' TGCATCTGCCTCCCCATATT 3'
Reverse 5' AGTGGGCGGGCAATGTAG 3'
Probe 5' CTCGGACACCACACCCTGCTGCT 3'
For quantification of mRNAs by LDA, cDNA was synthe-
sised from RNA obtained from liver, tonsil and thrombin-
treated aortic endothelial cells using a high capacity cDNA
archive kit (Applied Biosystems, Product Number
4322171) according to the manufacturer's protocols. To
assess the fidelity of LDAs to quantitatively detect small
changes in copy number, cDNA from liver was then
diluted to make a 2-fold dilution series, so the concentra-
tions per well on the LDAs were 1, 0.5, 0.25, 0.125,
0.0625 and 0.03125 ng/µl. To assess dynamic range,
cDNA from tonsil underwent a 10-fold dilution series, so
the concentrations used were 1, 0.1, 0.01, 0.001, 0.0001
and 0.00001 ng/µl. For the primary cell studies, the con-
centration of cDNA used was 0.08 ng/µl for both conven-
tional and LDA QRT-PCR.
LDA technology allows the simultaneous measurement of
expression of up to 384 genes in a single sample. Each
array has eight channels, allowing between one to eight
cDNA samples to be loaded. Each channel services 48
wells, with the possibility of having all 48 wells contain-
ing different primer probe sets. For this study the Low
Density Immune Profiling Array was used; Product
number 4342510. In these arrays, each channel, with 48
wells, contains pre-designed primer probe sets for 12 dif-
ferent genes (in quadruplicate). Therefore, each array con-
sists of 96 pre-designed TaqMan gene expression assays in
quadruplicate. The targets include cytokines, chemokines,
growth factors, immune regulators, apoptosis markers,
ischemia markers, tissue-specific markers, as well as
housekeeping genes. To run the arrays, cDNA is added to
the PCR master mix and the resulting mixture is then
added to one or all of the eight channels on the array. The
samples are loaded, by centrifugation into the wells that
contain the lyophilised primer probe sets. The wells are
then sealed, and the array is run on the ABI 7900HT. All
of these steps were carried out according to the manufac-
turer's protocol.
Data analysis
The starting mRNA copy number (Cn) of a target
sequence for conventional and LDA QRT-PCR is estab-
lished by determining the fractional PCR threshold cycle
(Ct) number at which the fluorescent signal generated
during the replication process exceeds a threshold value.
The initial amount of target mRNA in each sample is then
estimated from the experimental Ct by extrapolation from
a global standard curve generated using known amounts
of genomic DNA [8].
Linear regression data analysis for 2 and 10-fold dilutions
were determined using PRISM (Graphpad Software Inc.,
CA, USA).
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